Switching Evidence on Trial: What FDA’s decisions regarding JUUL and blu, and the outcome of Wages vs. FDA mean for Nicotine product marketing authorizations in the USA.
Company: ARAC – Applied Research and Analysis Company The election of Donald Trump in November 2024 prompted great anticipation in the nicotine and tobacco industry among those hoping that the incoming administration would overhaul the beleaguered PMTA process. To many, it seemed that the Reduction In Force orders would force the agency to reduce the…